In consistence with our study, AIM2 was demonstrated to inhibit proliferation and tumorigenicity in breast cancer, renal carcinoma, and prostate cancer (Chen et al., 2006; Ponomareva et al., 2013; Chai et al., 2018). The gene discussed is AIM2; the disease is breast carcinoma.